Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...